A phase II trial testing the thermal dose parameter CEM43°T90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy

P. D. Maguire, T. V. Samulski, L. R. Prosnitz, E. L. Jones, G. L. Rosner, B. Powers, L. W. Layfields, D. M. Brizel, S. P. Scully, J. M. Harrelson, M. W. Dewhirst

Research output: Contribution to journalArticlepeer-review

Abstract

We prospectively evaluated whether delivering a thermal dose of ≥ 10 cumulative equivalent minutes at 43°C to > 90% of the tumour sites monitored (CEM43°T90) would produce a pathologic complete response (pCR) in ≥ 75% of high-grade soft tissue sarcomas treated pre-operatively with thermoradiotherapy. The impact of thermal dose on local failure (LF), distant metastasis (DM), and toxicity was also assessed. Thirty-five patients ≥ 18 years old with grade 2 or 3 soft tissue sarcomas accessible for invasive thermometry were enrolled on the protocol. All patients received megavoltage external beam radiotherapy (RT) in daily fractions of 1.8-2.0 Gy, five times a week, to a median total dose of 50 Gy and an initial hyperthermia treatment (HT) of 1 h duration utilizing the BSD 2000 with Sigma 60 or MAPA applicators at frequencies of 60-140 MHz. Further HT was given for patients with CEM43°T90 > 0.5 after initial HT ('heatable' patients), twice a week to a maximum of 10 HT or CEM43°T90 > 100. Of the 35 patients entered, 30 had heatable tumours, one of which was inevaluable for pCR or LF as the patient died of DM prior to surgery, leaving 29 evaluable patients. Of these 29 patients, 15 (52%) had a pCR (95% CI: 37-73%), significantly less than the projected rate of ≥ 75% (p = 0.02). Of the 25 heatable tumours that achieved CEM43°T90 ≥ 10, 14 (56%) had a pCR (95% CI: 39-78%) significantly less than the projected rate (p = 0.06). Three of the 29 patients (10%) with heatable tumours had a LF, versus 1/5 unheatable tumours (p = 0.48). Fourteen of the 30 patients (47%) with heatable tumours developed DM, versus 2/5 unheatable tumours (p = 1.00). Ten of the 30 patients (33%) with heatable tumours developed treatment-induced toxicity. Thus, no correlation of thermal dose with histologic response was observed. Prospective control of CEM43°T90 failed to achieve the projected pCR rate following pre-operative thermoradiotherapy for high-grade soft tissue sarcomas, despite excellent local control. Possible explanations for this outcome are discussed.

Original languageEnglish (US)
Pages (from-to)283-290
Number of pages8
JournalInternational Journal of Hyperthermia
Volume17
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Complete response
  • Hyperthermia
  • Metastasis
  • Radiation therapy

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II trial testing the thermal dose parameter CEM43°T<sub>90</sub> as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy'. Together they form a unique fingerprint.

Cite this